ArticleEnvironmental health perspectives2000
Metallothionein isoform 3 as a potential biomarker for human bladder cancer.
Article in Environmental health perspectives, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- Pooled it
- Protein interactions with metallothionein-3 promote vectorial active transport in human proximal tubular cells.PloS one · 2022Article
- Metallothionein-3 promotes cisplatin chemoresistance remodelling in neuroblastoma.Scientific reports · 2021Article
- Interplay between Carbonic Anhydrases and Metallothioneins: Structural Control of Metalation.International journal of molecular sciences · 2020Review
- Metallothionein Genes are Highly Expressed in Malignant Astrocytomas and Associated with Patient Survival.Scientific reports · 2019Article
- Specificity of the Metallothionein-1 Response by Cadmium-Exposed Normal Human Urothelial Cells.International journal of molecular sciences · 2019Article
- Metallothionein 3 Is a Hypoxia-Upregulated Oncogene Enhancing Cell Invasion and Tumorigenesis in Human Bladder Carcinoma Cells.International journal of molecular sciences · 2019Article
- The roles of metallothioneins in carcinogenesis.Journal of hematology & oncology · 2018Review
- Metallothionein 3 expression in normal skin and malignant skin lesions.Pathology oncology research : POR · 2015Article
- Metallothionein-3 Increases Triple-Negative Breast Cancer Cell Invasiveness via Induction of Metalloproteinase Expression.PloS one · 2015Article
- Cadmium as a possible cause of bladder cancer: a review of accumulated evidence.Environmental science and pollution research international · 2014Review
- Role of metallothioneins in benign and malignant thyroid lesions.Thyroid research · 2012Article
- Differences in the epigenetic regulation of MT-3 gene expression between parental and Cd+2 or As+3 transformed human urothelial cells.Cancer cell international · 2011Article
- Location-specific epigenetic regulation of the metallothionein 3 gene in esophageal adenocarcinomas.PloS one · 2011Article
- Absence of Metallothionein 3 Expression in Breast Cancer is a Rare, But Favorable Marker of Outcome that is Under Epigenetic Control.Toxicological and environmental chemistry · 2010Article
- Reaction of human metallothionein-3 with cisplatin and transplatin.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2009Article
- Metallothionein isoform II expression in hyperplastic, dysplastic and neoplastic prostatic lesions.Journal of clinical pathology · 2006Article
- DBC1 re-expression alters the expression of multiple components of the plasminogen pathway.Oncogene · 2006Article
- Metallothionien 3 expression is frequently down-regulated in oesophageal squamous cell carcinoma by DNA methylation.Molecular cancer · 2005Article
- Identification of mouse brain proteins associated with isoform 3 of metallothionein.Protein science : a publication of the Protein Society · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The goal of the present study was to determine if the expression of metallothionein isoform 3 (MT-3) might serve as a biomarker for human bladder cancer. To accomplish this goal, we defined the localization and expression of MT-3 protein and mRNA using fresh and archival biopsy specimens obtained from patients undergoing differential diagnosis for a variety of bladder disorders. We used immunohistochemistry, immunoblot, and RT-PCR analysis to define the localization and expression of MT-3 protein and mRNA. Immunohistochemical analysis disclosed no immunoreactivity for MT-3 in normal bladder cells. The absence of MT-3 expression in the normal bladder was further confirmed by demonstrating that MT-3 mRNA could not be detected using reverse transcriptase-polymerase chain reaction (RT-PCR) or MT-3 protein using immunoblot. Immunohistochemistry also disclosed no immunoreactivity for MT-3 in archival biopsy specimens from patients with interstitial cystitis and related disorders. Immunohistochemical analysis demonstrated that MT-3 was expressed in carcinoma in situ (CIS), high-grade bladder cancer, low-grade bladder cancer, and dysplastic lesions. MT-3 immunostaining was intense in both CIS and high-grade bladder cancer, and low to moderate in low-grade bladder cancer and dysplastic lesions. We determined MT-3 mRNA expression in a subset of these bladder cancer specimens; expression was elevated as compared to that of the housekeeping gene, ss-actin. The cDNA from the RT-PCR reaction primed for MT-3 contained a FokI restriction site, a site unique for MT-3 as compared to other MT family members. In conclusion, this study demonstrates that MT-3 is up-regulated in human bladder cancer and that this up-regulation increases with increasing tumor grade. The finding that MT-3 expression is minimal in normal bladder suggests that MT-3 might be developed into an effective biomarker for bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.